Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes
NCT ID: NCT00184574
Last Updated: 2017-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
603 participants
INTERVENTIONAL
2005-04-30
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NCT00097877
Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes
NCT01697618
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes
NCT01520753
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes
NCT00619697
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
NCT00097279
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biphasic insulin aspart
metformin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently treated with insulin
* Currently treated with Metformin
* HbA1c: 7.5-12.0%
Exclusion Criteria
* Metformin contraindications according to local practice
* TZDs within 6 months prior to randomisation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Bregenz, , Austria
Novo Nordisk Investigational Site
Feldkirch, , Austria
Novo Nordisk Investigational Site
Graz, , Austria
Novo Nordisk Investigational Site
Salzburg, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Bonheiden, , Belgium
Novo Nordisk Investigational Site
Brussels, , Belgium
Novo Nordisk Investigational Site
Genk, , Belgium
Novo Nordisk Investigational Site
Ghent, , Belgium
Novo Nordisk Investigational Site
Liège, , Belgium
Novo Nordisk Investigational Site
Pleven, , Bulgaria
Novo Nordisk Investigational Site
Sofia, , Bulgaria
Novo Nordisk Investigational Site
Brno, , Czechia
Novo Nordisk Investigational Site
Hradec Králové, , Czechia
Novo Nordisk Investigational Site
Prague, , Czechia
Novo Nordisk Investigational Site
Århus C, , Denmark
Novo Nordisk Investigational Site
Køge, , Denmark
Novo Nordisk Investigational Site
Odense, , Denmark
Novo Nordisk Investigational Site
Antibes, , France
Novo Nordisk Investigational Site
Boulogne-Billancourt, , France
Novo Nordisk Investigational Site
Brest, , France
Novo Nordisk Investigational Site
La Rochelle, , France
Novo Nordisk Investigational Site
Le Chesnay, , France
Novo Nordisk Investigational Site
Lille, , France
Novo Nordisk Investigational Site
Metz, , France
Novo Nordisk Investigational Site
Mougins, , France
Novo Nordisk Investigational Site
Narbonne, , France
Novo Nordisk Investigational Site
Nevers, , France
Novo Nordisk Investigational Site
Perpignan, , France
Novo Nordisk Investigational Site
Bad Heilbrunn, , Germany
Novo Nordisk Investigational Site
Beckum, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Dormagen, , Germany
Novo Nordisk Investigational Site
Dresden, , Germany
Novo Nordisk Investigational Site
Duisburg, , Germany
Novo Nordisk Investigational Site
Genthin, , Germany
Novo Nordisk Investigational Site
Kippenheim, , Germany
Novo Nordisk Investigational Site
München, , Germany
Novo Nordisk Investigational Site
Pohlheim, , Germany
Novo Nordisk Investigational Site
Saarbrücken, , Germany
Novo Nordisk Investigational Site
Saint Ingbert, , Germany
Novo Nordisk Investigational Site
Schönebeck, , Germany
Novo Nordisk Investigational Site
Völklingen, , Germany
Novo Nordisk Investigational Site
Würzburg, , Germany
Novo Nordisk Investigational Site
Budapest, , Hungary
Novo Nordisk Investigational Site
Debrecen, , Hungary
Novo Nordisk Investigational Site
Veszprém, , Hungary
Novo Nordisk Investigational Site
Catania, , Italy
Novo Nordisk Investigational Site
Florence, , Italy
Novo Nordisk Investigational Site
Gazi, , Italy
Novo Nordisk Investigational Site
Lucca, , Italy
Novo Nordisk Investigational Site
Milan, , Italy
Novo Nordisk Investigational Site
Padua, , Italy
Novo Nordisk Investigational Site
Roma, , Italy
Novo Nordisk Investigational Site
Roma, , Italy
Novo Nordisk Investigational Site
Salerno, , Italy
Novo Nordisk Investigational Site
Savigliano (CN), , Italy
Novo Nordisk Investigational Site
Terni, , Italy
Novo Nordisk Investigational Site
Udine, , Italy
Novo Nordisk Investigational Site
's-Hertogenbosch, , Netherlands
Novo Nordisk Investigational Site
Amersfoort, , Netherlands
Novo Nordisk Investigational Site
Brunssum, , Netherlands
Novo Nordisk Investigational Site
Hoogeveen, , Netherlands
Novo Nordisk Investigational Site
Roosendaal, , Netherlands
Novo Nordisk Investigational Site
Rotterdam, , Netherlands
Novo Nordisk Investigational Site
Lublin, , Poland
Novo Nordisk Investigational Site
Mazowieckie, , Poland
Novo Nordisk Investigational Site
Poznan, , Poland
Novo Nordisk Investigational Site
Szczecin, , Poland
Novo Nordisk Investigational Site
Warsaw, , Poland
Novo Nordisk Investigational Site
Zabrze, , Poland
Novo Nordisk Investigational Site
Ploieşti, Prahova, Romania
Novo Nordisk Investigational Site
Galati, , Romania
Novo Nordisk Investigational Site
Suceava, , Romania
Novo Nordisk Investigational Site
Târgu Mureş, , Romania
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Saint Petersburg, , Russia
Novo Nordisk Investigational Site
Saint Petersburg, , Russia
Novo Nordisk Investigational Site
Ljubljana, , Slovenia
Novo Nordisk Investigational Site
Albacete, , Spain
Novo Nordisk Investigational Site
Granada, , Spain
Novo Nordisk Investigational Site
L'Hospitalet de Llobregat, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Mostoles - Madrid -, , Spain
Novo Nordisk Investigational Site
Palma de Mallorca, , Spain
Novo Nordisk Investigational Site
San Juan, , Spain
Novo Nordisk Investigational Site
Valencia, , Spain
Novo Nordisk Investigational Site
Zaragoza, , Spain
Novo Nordisk Investigational Site
Biel, , Switzerland
Novo Nordisk Investigational Site
Interlaken-Unterseen, , Switzerland
Novo Nordisk Investigational Site
Sankt Gallen, , Switzerland
Novo Nordisk Investigational Site
Winterthur, , Switzerland
Novo Nordisk Investigational Site
Zurich, , Switzerland
Novo Nordisk Investigational Site
Ankara, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Bursa, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Bradford, , United Kingdom
Novo Nordisk Investigational Site
Brighton, , United Kingdom
Novo Nordisk Investigational Site
Bristol, , United Kingdom
Novo Nordisk Investigational Site
Cosham, , United Kingdom
Novo Nordisk Investigational Site
Dundee, , United Kingdom
Novo Nordisk Investigational Site
Plymouth, , United Kingdom
Novo Nordisk Investigational Site
Salford, , United Kingdom
Novo Nordisk Investigational Site
Sheffield, , United Kingdom
Novo Nordisk Investigational Site
Watford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab. 2007 Sep;9(5):630-9. doi: 10.1111/j.1463-1326.2006.00654.x.
Cucinotta D, Smirnova O, Christiansen JS, Kanc K, le Devehat C, Wojciechowska M, Lopez de la Torre M, Liebl A. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab. 2009 Jul;11(7):700-8. doi: 10.1111/j.1463-1326.2009.01035.x. Epub 2009 May 19.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIASP-1440
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.